Skip to main content
Clinical Trials/PER-099-03
PER-099-03Completed未知

RANDOMIZED STUDY OF PHASE II / III OF PACLITAXEL + CARBOPLATINO WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH ADVANCED PULMON CANCER OR METASTASIC NO SCAMOSO NSCLC.

EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 sites0 target enrollmentStarted: February 27, 2004Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • not contemplated

Exclusion Criteria

  • not contemplated

Investigators

Sponsor
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),

Similar Trials

Active, not recruiting
Phase 1
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.MedDRA version: 18.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864Metastatic Breast Cancer
EUCTR2012-003262-41-GBGenentech, Inc.179
Active, not recruiting
Phase 1
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.MedDRA version: 15.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast Cancer
EUCTR2012-003262-41-ESGenentech, Inc.180
Active, not recruiting
Phase 1
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.Metastatic Breast Cancer
EUCTR2012-003262-41-BEGenentech, Inc.180
Active, not recruiting
Phase 1
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.MedDRA version: 19.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast Cancer
EUCTR2012-003262-41-CZGenentech, Inc.180
Active, not recruiting
Phase 1
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.Metastatic Breast Cancer
EUCTR2012-003262-41-ATGenentech, Inc.180